Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT6 | P42226 | 1/20 | 0.51 |
| ▸ | EML4 | Q9HC35 | 1/20 | 0.50 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.50 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.49 |
| ▸ | TTK | P33981 | 1/20 | 0.49 |
| ▸ | SYK | P43405 | 4/20 | 0.46 |
| ▸ | LCK | P06239 | 7/20 | 0.46 |
| ▸ | JAK3 | P52333 | 6/20 | 0.46 |
| ▸ | EGFR | P00533 | 5/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.44 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.41 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10169520 | 0.89 | PARP1 (0.48) | STAT6EML4ALKSYKLCK | |
| SCHEMBL10169338 | 0.83 | SYK (0.52) | STAT6EML4ALKSYKEGFR | |
| SCHEMBL20750855 | 0.82 | SYK (0.56) | SYK | |
| SCHEMBL18926127 | 0.82 | EML4 (0.50) | STAT6EML4ALKMAP4K1TTK | |
| SCHEMBL18926126 | 0.82 | EML4 (0.50) | STAT6EML4ALKMAP4K1TTK | |
| SCHEMBL2713094 | 0.82 | SYK (0.56) | SYK | |
| SCHEMBL10169447 | 0.80 | JAK3 (0.41) | LCKJAK3EGFRPARP1BTK | |
| SCHEMBL10169403 | 0.79 | SYK (0.44) | SYK | |
| SCHEMBL10169425 | 0.79 | FLT3 (0.55) | EML4ALKSYKJAK3BRD4 | |
| SCHEMBL10169371 | 0.78 | STAT6 (0.55) | STAT6EML4ALKSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586751-B2 | Nicotinamide compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-11-19 | — | — | US | disclosed |
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MEYERS SQUIBB COMPANY | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | NADK, BTK, NAMPT | STAT6 438/4885EML4 4878/4885ALK 2861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.